Cognitive Decline

According to the Center for Disease Control, subjective cognitive decline affects approximately 11.1% of the United States population, with this percentage rising by 7% among individuals aged over 65. Over the years, the number of people experiencing subjective cognitive decline has continued to increase. While the causes of cognitive decline vary, age-related cognitive issues can stem from several factors, including the accumulation of protein aggregates such as Lewy bodies, Beta amyloid, and Tau, a decrease in the neurotrophic factor Brain-Derived Neurotrophic Factor (BDNF), and diminished blood flow leading to reduced energy production in the brain. Among older individuals, a decrease in serum BDNF has been linked to both cognitive decline and depression.


In those over 65, subjective cognitive decline significantly impacts daily life, affecting tasks, chores, speech, and the ability to live independently. While age-related decline is common in the elderly, a continuous reduction in subjective cognitive abilities can lead to mild cognitive decline, a contributing factor in the onset of dementia.


CNS Curative Technologies is presently developing formulations containing a blend of nootropics aimed at achieving several goals:


  1. Increasing brain energy production by elevating levels of neurotrophic factors like BDNF and NGF.
  2.  Elevating BDNF levels is linked to heightened oxygen consumption and ATP production in neurons.
  3.  BDNF plays a role in the formation of long-term memories, and reduced levels contribute to brain aging. Our formulation intends to heighten BDNF levels, which correlates with improved cognitive function.
  4.  In preclinical models of neurodegeneration, our formulation, comprising a stack of nootropics, has shown promise in reducing the number of protein aggregates like Lewy bodies.
  5. The formulation is expected to reduce brain fog in people with chronic fatigue syndrome and other conditions

Our pipeline product, named “AdaptNeuro,” is presently in the preclinical stage involving animal models of aging. This formulation aims to enhance the brain’s absorption of active ingredients, reducing cognitive decline, minimizing protein aggregation in the brain, bolstering executive brain function, and helping neurons adapt to a flourishing environment.


  1. Hale et al., 2020, Cognitive impairment in the US: Lifetime risk, age at onset, and years impaired.
  2. Crimmins E.M., Saito Y., Ki J., Kim J.K. Change in cognitively healthy and cognitively impaired life expectancy in the United States: 2000–2010. SSM – Population Health. 2016;2:793–797.
  3. Shimada et al., Depressive symptoms and cognitive performance in older adults, Journal of psychiatric research, 57:149-56. doi: 10.1016/j.jpsychires.2014.06.004.
  4. Molinari et al., 2020, The Role of BNDF on Aging-Modulation Markers, Brain Sci, 2020 10(5); 285;
  5. Swain, Oma, S, Tapia K, Dagda RY, Dagda, RK.  J ., Brain-derived neurotrophic factor protects neurons by stimulating mitochondrial function through protein kinase A Neurochem. 2023 Oct;167(1):104-125. doi: 10.1111/jnc.15945.
  6. Vazquez-Mayorga E, Grigoruta M, Dagda R, Martinez B, Dagda RK.   Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats
  7. Ruben K Dagda, Raul Y Dagda , Emmanuel Vazquez-Mayorga , Bridget Martinez , Aine
  8. Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats. Int J Mol Sci, 2022 Dec 30;24(1):690  doi: 10.3390/ijms24010690.